Key Takeaways
- Soft quarter, back-half loaded: Revenue dipped QoQ as a one-time commercial sales spike in Q1 did not repeat, the new French facility startup slipped a few weeks, and Bavla shipments were scheduled for H2. Management expects a materially stronger second half.
- EDQM clearance unlocks the Bavla story: The successful EDQM audit, alongside the earlier PMDA approval, means Bavla is now approved by all major global authorities. Management targets INR400–450 crores of revenue from Bavla next fiscal year.
- French facility is the near-term margin drag: Startup delays pushed the first GMP batch into the current quarter, leaving the facility EBITDA-negative for the full year. Breakeven is expected only toward year-end, with a EUR2 crore revenue target for FY25.
- Margins compressed, recovery promised by FY26: Inflation, wage hikes, and the French drag hit profitability. Management is targeting a 25% EBITDA margin by FY26, with an increase beginning next fiscal year.
- What to watch next quarter: The EDQM green light (expected in ~6 weeks), the first customer clinical batch from France, and whether H2 shipment volumes from India materialize as guided.
Bavla Facility: The Regulatory Catalyst
- EDQM audit passed: The late-September audit concluded with only procedural recommendations categorized as "others," not even minor observations. The authority has six weeks from the company's reply submission to issue the final green light.
- PMDA approval already in hand: The Japanese PMDA audit in early August was completed successfully with no critical or major observations; the final report is expected to close imminently.
- Now a globally approved site: With EDQM and PMDA added to existing approvals, Bavla is now approved by all major regulatory authorities worldwide, a status management believes makes it one of the best-qualified facilities in India.
- Revenue target set: Management expects INR400–450 crores of revenue from Bavla in the next financial year (FY25), driven by the reopened European and Japanese markets plus internal collaboration with Carbogen Amcis.
- Customer enthusiasm confirmed at CPhI: At CPhI Barcelona two weeks ago, both old and new customers reacted with "great enthusiasm" to the EDQM and PMDA news, and management expects a wave of proposals to convert into orders once the formal clearance arrives.
Paolo Armanino: "Needless to say that there was a great enthusiasm honestly by the customer. So the old customer, they are really very happy about this news, especially with EDQM, but also the PMDA because the Bavla today is approved by all the major authorities worldwide."
French Facility: Delayed Start, Gradual Ramp
- Startup postponed by a few weeks: Issues discovered in the greenfield new build required fixes before operations could begin, pushing the first GMP batch into the current quarter and the first customer clinical batch to next week.
- Full-year EBITDA will be negative: The delay means the facility will remain EBITDA-negative for the entirety of FY24, acting as a consolidated margin drag. Management expects to approach breakeven only toward the end of the financial year.
- FY25 target is EUR2 crore revenue: Management aims for at least EUR2 crore in revenue from the French facility next fiscal year, which at that level would generate slightly positive EBITDA. A strong project pipeline with positive customer feedback underpins the target.
- Capitalization imminent: The entire French project currently sits in CWIP and will be capitalized when commercial production begins this quarter, increasing depreciation charges to the P&L as a non-cash item.
Pascal Villemagne: "We discovered a few things that shifting that we had to fix before we started. So that was the reasons why we had to postpone the startup for a few weeks."
Segment & Margin Performance
- Q2 revenue softer than Q1: Q1 benefited from an exceptional level of commercial sales that did not repeat in Q2, making the sequential comparison look weak even though the underlying business trajectory was stable.
- Carbogen Amcis revenue slightly below expectations: The French facility delay was the primary driver of the miss, though H1 revenue still came in ahead of the prior year.
- European profitability under pressure: High inflation, salary increases, and elevated fuel costs compressed margins, and the annual pricing cycle creates a lag between cost increases and customer pass-through.
- Cholesterol mix diluted analogue margins: Growth in the cholesterol and vitamin D analogues segment was driven by feed-grade cholesterol, which carries lower margins than the higher-value analogue business.
- India margins expected positive in H2: Most India shipments are scheduled for the second half, and the consolidated margin profile should improve as those higher-margin volumes flow through.
- Employee expense swing was largely FX-driven: Of the INR32 crores increase in employee expenses, approximately INR30 crores came from Swiss franc-to-INR exchange rate fluctuation, not from headcount or wage inflation alone.
- Finance costs rose on global rates: Higher interest rates globally increased the company's finance costs during the quarter.
ADC & Other Growth Drivers
- Japanese ADC program starting January 2024: The first campaign with the Japanese customer is ready to begin in the first quarter of calendar 2024, with the contract expected to drive a large portion of revenue through 2029–2030. Management cited confidentiality in declining to quantify volumes.
- ADC capex capitalizing in Q4: The Swiss ADC expansion will be capitalized in Q4 of the current financial year, at which point those assets will begin generating revenue.
- Bavla molecule shipment timing: One of the largest molecules manufactured at Bavla had zero shipments in H1 because the customer requires deliveries only in the second half, creating a natural H2 revenue uptick.
- No major capex remaining: With the French facility, ADC expansion, and Bavla upgrades all nearing completion, the company expects only maintenance capex and digital transformation spending going forward, setting the stage for free cash flow generation from next fiscal year.
Pascal Villemagne: "Unfortunately, this information could be related to volumes and that kind of information, we are binding with our customer to confidentiality. What I can tell you is it's going to have a major increment on our top line revenues with several kind of mediums in the future."
Operational Improvements & Internal Collaboration
- Leaner operating model at Carbogen Amcis: A new organization structure is being implemented alongside digital tools, including SAP, which has been running for almost a year and is expected to reduce FX impact starting next year after its full go-live in H1 FY25.
- Internal collaboration between arms: The EDQM clearance opens potential for extensive collaboration between Carbogen Amcis and Dishman Carbogen Amcis, with sales teams now working together to fill capacity gaps across the group.
- Bavla facility facelift complete: Management described Bavla as one of the best facilities in India today in terms of both technical capabilities and overall qualifications, positioning it to capture the post-EDQM opportunity.
Sanjay Majmudar: "It looks like, I would believe, one of the best facilities in India today in terms of the technical as well as the overall qualifications."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EDQM green light | Final certification following successful audit with only procedural recommendations | ~6 weeks from reply submission (authority timeline, not company-controlled) |
| French facility breakeven | Approach breakeven on the new facility | By end of current financial year (FY24) |
| French facility revenue | At least EUR2 crore revenue, slightly positive EBITDA | FY25 |
| Bavla facility revenue | INR400–450 crores of revenue | FY25 |
| India H2 catch-up | Positive consolidated margins as more shipments go out | H2 FY24 |
| ADC revenue start | First campaign with Japanese customer begins; assets generating revenue | January 2024 (Q4 FY24) |
| Free cash flow | Free cash flow generation begins as capex cycle ends and returns commence | FY25 |
| EBITDA margin target | 25% EBITDA margin, with increase beginning next fiscal year | FY26 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue from operations | ₹587 cr, vs ₹614 cr in Q2 FY23 |
| EBITDA | ₹63 cr, margin at ~10.5% |
| Employee expenses increase | ₹32 cr YoY, ~₹30 cr from Swiss franc forex fluctuation |
| Finance cost | ₹27.5 cr, vs ₹20 cr in Q2 FY23 |
| Carbogen Amcis CRAM revenue | ₹437 cr, flattish vs Q2 FY23 |
| Carbogen Amcis Group H1 FY24 revenue | ~₹1,000 cr, +24.5% YoY |
| Cholesterol and vitamin D analogues revenue | ₹87 cr, +35% YoY from ₹64 cr |
| Cholesterol and vitamin D analogues H1 FY24 revenue | ₹180 cr, +40% YoY from ₹128 cr |
| Carbogen Amcis Group EBITDA margin | 12.2%, vs 14.6% in Q2 FY23 |
| Cholesterol and vitamin D analogues margin | ~10%, vs 18% in Q2 FY23 |
| Full-year capex guidance | ~₹3 cr, with ₹1.7 cr spent in H1 |
| French facility FY25 revenue target | At least €2 cr |
| French facility current-year revenue forecast | Close to €8 million, maybe a little more |
| CWIP | ₹900 cr, expected to drop to not more than ₹200 cr by March (per an analyst's math) |
| EBITDA margin target of 25% | FY '26 |